Small-Sided Football Games Tested as Hybrid Exercise Therapy for Type 2 Diabetes
A completed RCT tests whether small-sided football sessions 3x/week improve glucose control and metabolic health in T2DM patients on GLP-1 and SGLT2 drugs.
Summary
This completed randomized controlled trial investigated whether a fun, game-based exercise format — small-sided football played three times per week for 14 weeks — could meaningfully improve blood glucose regulation, body composition, and cardiovascular fitness in adults aged 40-70 with type 2 diabetes. A key novelty was examining how the exercise interacted with modern diabetes medications, specifically GLP-1 receptor agonists and SGLT2 inhibitors. Up to 800 participants were enrolled and split into a football group or control group. Assessments included continuous glucose monitoring, DEXA body composition scans, peak oxygen uptake, and muscle biopsies in a subset. Results could help clinicians design exercise prescriptions that complement — or enhance — pharmacotherapy for metabolic disease.
Detailed Summary
Type 2 diabetes affects hundreds of millions globally and dramatically elevates the risk of cardiovascular disease, kidney failure, and early death. While medications like GLP-1 receptor agonists and SGLT2 inhibitors have transformed pharmacological management, the additive or interactive effects of structured exercise alongside these drugs remain poorly characterized. This study aimed to fill that gap with a rigorously designed trial.
Researchers at the University of the Faroe Islands enrolled adults aged 40-70 with a T2DM diagnosis within the last decade, excluding those with severe vascular complications. Up to 800 participants were randomized in a 60/40 ratio — with stratification by age, sex, and GLP-1 agonist use — into either a football intervention group or a passive control group. The football group attended 60-minute small-sided game sessions three times weekly for 14 weeks.
Outcome measures were comprehensive: blood pressure, fasting blood parameters, DEXA-derived body composition, peak VO2, Yo-Yo intermittent endurance testing, and 24-hour continuous glucose monitoring. A subset of participants underwent muscle biopsies to assess intramuscular metabolic adaptations, providing mechanistic depth rare in exercise-diabetes trials.
The hybrid training model is clinically appealing because small-sided football combines high-intensity intermittent efforts with social engagement, potentially improving adherence compared to traditional gym-based protocols. Stratification by GLP-1 agonist use is especially timely given the explosive uptake of semaglutide and tirzepatide — understanding whether exercise amplifies or merely complements their metabolic effects is critical for treatment optimization.
While the trial is listed as completed, full results have not yet been published. Findings could meaningfully inform future clinical guidelines on integrating structured exercise with modern T2DM pharmacotherapy, offering both clinicians and patients a more holistic management framework.
Key Findings
- Small-sided football 3x/week for 14 weeks was tested as a structured exercise intervention in T2DM adults aged 40-70.
- Study uniquely examined exercise interactions with GLP-1 receptor agonists and SGLT2 inhibitors simultaneously.
- Outcomes included 24-hour continuous glucose monitoring, DEXA scans, VO2 peak, and muscle biopsies.
- Up to 800 participants randomized in a 60/40 ratio with stratification by age, sex, and GLP-1 treatment status.
- Trial is completed but published results are not yet available from the abstract alone.
Methodology
Randomized controlled trial with up to 800 participants randomized 60/40 into football or control groups using stratified randomization by age, sex, and GLP-1 agonist use. The 14-week intervention consisted of three 60-minute small-sided football sessions per week, with pre- and post-intervention assessments using DEXA, CGM, cardiorespiratory fitness testing, and muscle biopsies in a subset.
Study Limitations
Summary is based on the abstract only; full results and primary outcome data have not been reviewed. The trial is listed as completed but no published findings were available, making it impossible to assess efficacy or effect sizes. Generalizability may be limited given the Faroese study population and exclusion of participants with significant vascular complications.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.